Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04465370 · ClinicalTrials.gov registry record
Pediatric Cardiac Output Monitoring Observational Study
A clinical trial, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- 89
- Enrollment target
NCT04465370 is a clinical trial that has completed, run by Edwards Lifesciences. The registered enrollment target is 89 participants.
The verdict
NCT04465370 has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, in order to expand the indications of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric population 12 to 18 years of age.
Interventions
- DEVICE Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2023-01-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04465370
The ClinicalTrials.gov registry entry for NCT04465370 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight is the first listed.
NCT04465370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04465370 about?
NCT04465370 is a clinical study titled "Pediatric Cardiac Output Monitoring Observational Study". To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, in order to expand the indications of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric population 12 to 18 years o...
What is the current status of trial NCT04465370?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2020-09-02. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT04465370?
The interventions under investigation include: Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight (DEVICE).
Who is sponsoring clinical trial NCT04465370?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.